Vaccination against cancer "caused" the body: it did not return after the introduction of tumor cells

Vaccination against cancer "caused" the body: it did not return after the introduction of tumor cell

Researchers from Tufts University have created a new mRNA cancer vaccine, which is designed to deliver a useful load to lymph nodes rather than livers. Mice tests have shown significant inhibition of tumors, with cancer completely disappearing in a decent percentage of cases.

Biologists have improved the immune response by changing the route and destination of MRNA in the body. In most cases, MRNA enters the liver, but a more effective immune response can be obtained by sending molecules to a lymphatic system where immune cells are better trained to recognize "wrecks".

To do this, scientists have changed the recipe for lipid nanoparticles that transport MRNA, which has caused different molecules from the bloodstream to gather on the surface of the particles that, in turn, are associated with receptors in different organs. After testing several combinations of properties, biologists have created lipid nanoparticles that have contributed to the delivery to lymph nodes compared to livers in a ratio of three to one.

There, the vaccine has absorbed about a third of the dendrite cells and macrophages, and these key immune cells teach B- and T-cells to target certain antigens, leading to a stronger immune response to cancer.

Mice tests with metastatic melanoma showed that treatment significantly inhibits tumors in combination with another treatment, anti-PD-1 therapy. Moreover, full remission came in 40% of the cases, and cancer did not recur, even after scientists later injected metastatic tumor cells into them, so scientists not only cured cancer, but also "caused" the organisms of experimental animals.